6.01 USD
+0.13 (+2.3%)
We assign a fundamental rating of 4 out of 10 to PROF. PROF was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While PROF has a great health rating, there are worries on its profitability. PROF is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year PROF has reported negative net income.
In the past year PROF has reported a negative cash flow from operations.
In the past 5 years PROF always reported negative net income.
In the past 5 years PROF always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -93.00%, PROF is doing worse than 78.19% of the companies in the same industry.
With a Return On Equity value of -122.40%, PROF is not doing good in the industry: 66.49% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -93% | ||
| ROE | -122.4% | ||
| ROIC | N/A |
ROA(3y)-49.72%
ROA(5y)-41.04%
ROE(3y)-64.26%
ROE(5y)-50.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PROF has a better Gross Margin (72.49%) than 81.38% of its industry peers.
PROF's Gross Margin has improved in the last couple of years.
PROF does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.33%
GM growth 5Y2.85%
2. Health
2.1 Basic Checks
PROF does not have a ROIC to compare to the WACC, probably because it is not profitable.
PROF has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PROF has more shares outstanding
Compared to 1 year ago, PROF has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.60, we must say that PROF is in the distress zone and has some risk of bankruptcy.
PROF's Altman-Z score of -0.60 is in line compared to the rest of the industry. PROF outperforms 44.68% of its industry peers.
PROF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.6 |
ROIC/WACCN/A
WACC7.64%
2.3 Liquidity
PROF has a Current Ratio of 4.18. This indicates that PROF is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PROF (4.18) is better than 72.34% of its industry peers.
A Quick Ratio of 3.34 indicates that PROF has no problem at all paying its short term obligations.
PROF has a Quick ratio of 3.34. This is in the better half of the industry: PROF outperforms 70.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.18 | ||
| Quick Ratio | 3.34 |
3. Growth
3.1 Past
PROF shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
Looking at the last year, PROF shows a very strong growth in Revenue. The Revenue has grown by 59.14%.
PROF shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.67% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.58%
Revenue 1Y (TTM)59.14%
Revenue growth 3Y15.83%
Revenue growth 5Y20.67%
Sales Q2Q%86.76%
3.2 Future
PROF is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.32% yearly.
PROF is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 56.05% yearly.
EPS Next Y-39.78%
EPS Next 2Y0.85%
EPS Next 3Y15.93%
EPS Next 5Y23.32%
Revenue Next Year51.68%
Revenue Next 2Y82.69%
Revenue Next 3Y73.26%
Revenue Next 5Y56.05%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PROF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PROF. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as PROF's earnings are expected to grow with 15.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.85%
EPS Next 3Y15.93%
5. Dividend
5.1 Amount
No dividends for PROF!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PROF (11/21/2025, 8:00:01 PM)
6.01
+0.13 (+2.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners45.81%
Inst Owner Change-18.83%
Ins Owners17.71%
Ins Owner Change0%
Market Cap181.44M
Revenue(TTM)14.30M
Net Income(TTM)-39.34M
Analysts80
Price Target11.31 (88.19%)
Short Float %3.61%
Short Ratio7.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.31%
Min EPS beat(2)-40.1%
Max EPS beat(2)29.47%
EPS beat(4)2
Avg EPS beat(4)1.24%
Min EPS beat(4)-40.1%
Max EPS beat(4)42.88%
EPS beat(8)4
Avg EPS beat(8)-5.3%
EPS beat(12)7
Avg EPS beat(12)-2.31%
EPS beat(16)10
Avg EPS beat(16)0.34%
Revenue beat(2)1
Avg Revenue beat(2)-16.59%
Min Revenue beat(2)-38.03%
Max Revenue beat(2)4.86%
Revenue beat(4)1
Avg Revenue beat(4)-15.52%
Min Revenue beat(4)-38.03%
Max Revenue beat(4)4.86%
Revenue beat(8)2
Avg Revenue beat(8)-13.01%
Revenue beat(12)2
Avg Revenue beat(12)-18.46%
Revenue beat(16)3
Avg Revenue beat(16)-19.86%
PT rev (1m)1.97%
PT rev (3m)0.14%
EPS NQ rev (1m)13.18%
EPS NQ rev (3m)-64.71%
EPS NY rev (1m)-1.14%
EPS NY rev (3m)-39.64%
Revenue NQ rev (1m)6.3%
Revenue NQ rev (3m)-36.73%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12.69 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.64 | ||
| P/tB | 5.67 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.34
EYN/A
EPS(NY)-1.1
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0.47
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -93% | ||
| ROE | -122.4% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.49% | ||
| FCFM | N/A |
ROA(3y)-49.72%
ROA(5y)-41.04%
ROE(3y)-64.26%
ROE(5y)-50.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.33%
GM growth 5Y2.85%
F-Score4
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.18 | ||
| Quick Ratio | 3.34 | ||
| Altman-Z | -0.6 |
F-Score4
WACC7.64%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.58%
EPS Next Y-39.78%
EPS Next 2Y0.85%
EPS Next 3Y15.93%
EPS Next 5Y23.32%
Revenue 1Y (TTM)59.14%
Revenue growth 3Y15.83%
Revenue growth 5Y20.67%
Sales Q2Q%86.76%
Revenue Next Year51.68%
Revenue Next 2Y82.69%
Revenue Next 3Y73.26%
Revenue Next 5Y56.05%
EBIT growth 1Y-27.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.37%
EBIT Next 3Y6.51%
EBIT Next 5Y28.76%
FCF growth 1Y-71.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71.34%
OCF growth 3YN/A
OCF growth 5YN/A
PROFOUND MEDICAL CORP / PROF FAQ
What is the fundamental rating for PROF stock?
ChartMill assigns a fundamental rating of 4 / 10 to PROF.
What is the valuation status for PROF stock?
ChartMill assigns a valuation rating of 0 / 10 to PROFOUND MEDICAL CORP (PROF). This can be considered as Overvalued.
What is the profitability of PROF stock?
PROFOUND MEDICAL CORP (PROF) has a profitability rating of 1 / 10.
What is the earnings growth outlook for PROFOUND MEDICAL CORP?
The Earnings per Share (EPS) of PROFOUND MEDICAL CORP (PROF) is expected to decline by -39.78% in the next year.